MX2022006005A - Metodo para producir virus de la influenza reagrupados. - Google Patents

Metodo para producir virus de la influenza reagrupados.

Info

Publication number
MX2022006005A
MX2022006005A MX2022006005A MX2022006005A MX2022006005A MX 2022006005 A MX2022006005 A MX 2022006005A MX 2022006005 A MX2022006005 A MX 2022006005A MX 2022006005 A MX2022006005 A MX 2022006005A MX 2022006005 A MX2022006005 A MX 2022006005A
Authority
MX
Mexico
Prior art keywords
influenza viruses
reassortant influenza
producing reassortant
producing
viruses
Prior art date
Application number
MX2022006005A
Other languages
English (en)
Inventor
Steven Rockman
Chi Ong
Erin Verity
Original Assignee
Seqirus Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seqirus Pty Ltd filed Critical Seqirus Pty Ltd
Publication of MX2022006005A publication Critical patent/MX2022006005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Un método para producir virus de la influenza reagrupados. También se proporcionan virus de la influenza reagrupados producidos de acuerdo con el método, así como vacunas basadas en los virus de la influenza reagrupados.
MX2022006005A 2019-11-18 2020-11-18 Metodo para producir virus de la influenza reagrupados. MX2022006005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19209839 2019-11-18
PCT/EP2020/082587 WO2021099419A1 (en) 2019-11-18 2020-11-18 Method for producing reassortant influenza viruses

Publications (1)

Publication Number Publication Date
MX2022006005A true MX2022006005A (es) 2022-10-27

Family

ID=68610061

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006005A MX2022006005A (es) 2019-11-18 2020-11-18 Metodo para producir virus de la influenza reagrupados.

Country Status (11)

Country Link
US (1) US20230000971A1 (es)
EP (1) EP4061930A1 (es)
JP (1) JP2023502650A (es)
KR (1) KR20220128613A (es)
CN (1) CN115380107A (es)
AU (1) AU2020389047A1 (es)
BR (1) BR112022009545A2 (es)
CL (1) CL2022001309A1 (es)
IL (1) IL293031A (es)
MX (1) MX2022006005A (es)
WO (1) WO2021099419A1 (es)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338296A (en) * 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
EP0711340A4 (en) * 1993-06-11 1998-02-04 Peter M Palese HIGH YIELDS OF INFLUENCE VIRUS
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ES2296390T3 (es) 1998-05-07 2008-04-16 Corixa Corporation Composicion coadyuvante y procedimiento para su uso.
AU764368B2 (en) 1999-09-24 2003-08-14 Smithkline Beecham Biologicals (Sa) Intranasal influenza virus vaccine
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
CA2890962A1 (en) 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP2170382B1 (en) * 2007-06-15 2013-07-31 Protheon Co., Ltd. Live vaccine comprising an attenuated influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法

Also Published As

Publication number Publication date
IL293031A (en) 2022-07-01
EP4061930A1 (en) 2022-09-28
KR20220128613A (ko) 2022-09-21
CN115380107A (zh) 2022-11-22
AU2020389047A1 (en) 2022-06-02
CL2022001309A1 (es) 2023-04-28
WO2021099419A1 (en) 2021-05-27
JP2023502650A (ja) 2023-01-25
BR112022009545A2 (pt) 2022-10-11
US20230000971A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
SA518400053B1 (ar) عملية مُحسنة لإنتاج حمض أكريليك
MY195408A (en) Novel Aspartokinase Variant and Method for Producing L- Amino Acid Using the Same
MY190659A (en) Method for producing biohydrocarbons
PH12019500493A1 (en) Solvate form of (r)-2-amino-3-phenylpropyl carbamate
EP4219526A3 (en) Method for preparing amg 416
PH12020500329A1 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
TW201612153A (en) Producing method of (R)-1,1,3-trimethyl-4-aminoindane
MY188962A (en) A microorganism of genus corynebacterium having an ability to produce l-arginine and an method for producing l-arginine using the same
WO2015107156A3 (de) Verfahren zur herstellung von arylpropenen
PH12017501678A1 (en) Recombinant microorganism for improved production of finie chemicals
CA3048452C (en) Processes for preparing glycoprotein-drug conjugates
WO2018093223A3 (ko) 엘더칼시톨의 제조방법 및 그를 위한 중간체
MX2019001465A (es) Metodo de produccion de cetoenoles ciclicos sustituidos con espirocetales.
MX2019015868A (es) Nueva psicosa-6-fosfato fosfatasa, composición para producir psicosa que incluye dicha enzima, método para producir psicosa usando dicha enzima.
WO2014086732A8 (en) Reassortant influenza a viren
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
MY177465A (en) A microorganism of the genus escherichia producing l-tryptophan and a method for producing l-tryptophan using the same
BR112017009205A2 (pt) método para preparar bifenilaminas a partir de azobenzenos por catálise de rutênio
EA202091834A1 (ru) Непрерывный способ получения тразодона
PH12020500042A1 (en) Method for preparing influenza working virus seed stock, method for preparing influenza vaccine using same seed stock, and virus seed stock prepared by same method
MY189749A (en) A microorganism of the genus corynebacterium producing l-lysine and a method for producing l-lysine using the same
WO2018007973A3 (en) Process and intermediates for preparing benzoxazepines
PH12020500414A1 (en) Method for producing influenza ha split vaccine
MX2022006005A (es) Metodo para producir virus de la influenza reagrupados.